Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (511-520 of 568) with videos related to

Pageof 57
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2021
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)Olga P Nyssen, Dino Vaira, Ángeles Pérez Aísa, et al.
Therapeutic Advances in Gastroenterology|February 24, 2026
Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA RegistryLucía Madero-Velázquez, Ruth de Francisco, Belen Herreros, et al.
Helicobacter|March 17, 2020
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)Olga P Nyssen, Ángeles Pérez-Aisa, Bojan Tepes, et al.
Revista Espanola De Enfermedades Digestivas|November 17, 2025
The implementation of PCR-guided therapy in the eradication of Helicobacter pylori: experience from the European Registry on H. pylori management (Hp-EuReg)Vladimir Milivojevic, Dusan Kekic, Sabir Sagdati, et al.
The American Journal of Gastroenterology|February 4, 2025
Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)Diego Casas Deza, Javier Alcedo, Miguel Lafuente, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 5, 2026
Higher doses of Bismuth and antibiotics do not improve H. pylori treatment effectiveness: results from the Hp-EuRegSamuel J Martínez-Domínguez, Ángel Lanas, Enrique Ceamanos, et al.
Gut|October 26, 2024
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)Llum Olmedo, Xavier Calvet, Emili Gené, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH studyMaría José Casanova, Óscar Nantes, Pilar Varela, et al.
Helicobacter|July 13, 2024
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)Samuel J Martínez-Domínguez, Olga P Nyssen, Ángel Lanas, et al.
Pageof 57

Showing results (511-520 of 568) with videos related to

Sort By:
Pageof 57
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 26, 2021
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)Olga P Nyssen, Dino Vaira, Ángeles Pérez Aísa, et al.
Therapeutic Advances in Gastroenterology|February 24, 2026
Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA RegistryLucía Madero-Velázquez, Ruth de Francisco, Belen Herreros, et al.
Helicobacter|March 17, 2020
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)Olga P Nyssen, Ángeles Pérez-Aisa, Bojan Tepes, et al.
Revista Espanola De Enfermedades Digestivas|November 17, 2025
The implementation of PCR-guided therapy in the eradication of Helicobacter pylori: experience from the European Registry on H. pylori management (Hp-EuReg)Vladimir Milivojevic, Dusan Kekic, Sabir Sagdati, et al.
The American Journal of Gastroenterology|February 4, 2025
Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)Diego Casas Deza, Javier Alcedo, Miguel Lafuente, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 5, 2026
Higher doses of Bismuth and antibiotics do not improve H. pylori treatment effectiveness: results from the Hp-EuRegSamuel J Martínez-Domínguez, Ángel Lanas, Enrique Ceamanos, et al.
Gut|October 26, 2024
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> infection between 2013 and 2021: results from the European registry on <i>H. pylori</i> management (Hp-EuReg)Llum Olmedo, Xavier Calvet, Emili Gené, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Alimentary Pharmacology & Therapeutics|April 24, 2023
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH studyMaría José Casanova, Óscar Nantes, Pilar Varela, et al.
Helicobacter|July 13, 2024
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)Samuel J Martínez-Domínguez, Olga P Nyssen, Ángel Lanas, et al.
Pageof 57